bche

BChE HDAC6-IN-2 is a selective and potent dual inhibitor of BChE and HDAC6 with neuroprotective and reactive oxygen species (ROS) scavenging activity. BChE HDAC6-IN-2 is a metal ion co-agonist that inhibits tau phosphorylation and can be used in the study of immune and neurological diseases.

AChE BChE MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively. [AChE BChE MAO-B-IN-1] had a neuroprotective effect and was not significantly cytotoxic.

AChE BChE-IN-10 is a potent dual inhibitor of AChE and BChE with IC50 values of 0.176, and 0.47 μM, respectively. AChE BChE-IN-10 exhibits good blood brain barrier permeability. AChE BChE-IN-10 can inhibit Aβ-aggregation.

hBChE-IN-2 is a butyrylcholinesterase (BChE) inhibitor and cannabinoid receptor 2 (CB2R) agonist with neuroprotective activity for the study of Alzheimer's disease-like neurological disorders.

1. Palmatine (Burasaine) is an inhibitor of dopamine generation. 2. Palmatine could potentially be developed for the treatment of flavivirus infections. 3. Palmatine has been used in the treatment of jaundice, dysentery, hypertension, inflammation, and liver-related diseases.

Garcinol also inhibits histone acetyltransferases (HATs, IC50= 7 μM) and p300 CPB-associated factor (PCAF, IC50 = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity. Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50s of 0.66 μM and 7.39 μM, respectively.

Lupinine is an alkaloid capable of counteracting ethanol anesthesia. Lupinine is an AChE and BChE inhibitor and potential CD69 activator found in species of Loranthus, Calia, and Lupinus. It may also inhibit heparin.

Gnetol competitivity inhibits butyrylcholinesterase (IC50: 1.3 uM). Gnetol has a strong inhibitory effect on murine tyrosinase activity. Gnetol significantly suppresses melanin biosynthesis in murine B16 melanoma cells. It is active in the inhibition of a

Histone acetyltransferase p300 Inhibitor 4c is a 2-aminothiazole derivative. Histone acetyltransferase p300 Inhibitor 4c inhibited hCA I, hCA II, AChE and BChE with Ki values of 0.008 ± 0.001, 0.124 ± 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 µM. 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 μM.

BChE-IN-25 (compound 4I) acts as a selective inhibitor of BChE, demonstrating an IC 50 of 3.77μM and exhibiting 22-fold greater selectivity towards BChE over AChE [1].

BChE-IN-3 is a selective, selective, time-dependent, pseudo-irreversible inhibitor of BChE butyrylcholinesterase (IC50: 56.9 nM).BChE-IN-3 exhibits borderline reversible (time-independent) inhibition of AChE acetylcholinesterase.

BChE-IN-6 (compound 12) is a highly effective inhibitor of BChE with a Ki value of 0.182 μM, and it exhibits significant chelating abilities towards Zn 2+. These characteristics make BChE-IN-6 a valuable tool for researchers in the field of Alzheimer's disease (AD) [1].

BChE-IN-4 is a highly potent inhibitor of the enzyme butyrylcholinesterase, capable of crossing the blood-brain barrier. It effectively reduces learning and memory impairments resulting from a deficiency in cholinergic activity in a mouse model. BChE-IN-4 holds promise for further investigation in the field of Alzheimer's disease research [1].

BChE-IN-5 is a potent and selective inhibitor of BChE (IC50: 2.8 nM) with a higher inhibitory effect on hBChE than hAChE and potential applications in Alzheimer's disease research.

AChE BChE-IN-14 (compound 13), a benzylisoquinoline alkaloid extracted from Fissistigma polyanthum roots, demonstrates inhibitory effects on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), coupled with antioxidant properties, and is pertinent to Alzheimer's disease research [1].

BChE-IN-21, a potent inhibitor of butyrylcholinesterase (BChE), exhibits an inhibition constant (IC50) of 0.14 ± 0.02 μM, indicating promise for research in Alzheimer's disease [1].

AChE BChE-IN-9 (Compound 7a) is a potent, orally active inhibitor of AChE and BChE, with IC50 values of 5.74 μM and 14.05 μM against hAChE and eqBChE, respectively. It also demonstrates effective antioxidant activity (IC50 = 57.35 μM), chelates iron, and modulates amyloid β 1-42 aggregation. Notably, AChE-IN-16 can cross the blood-brain barrier [1].

AChE BChE-IN-2 (Compound 13b) is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 0.96 ± 0.14 μM for AChE and 1.23 ± 0.23 μM for BChE.

AChE BChE BACE-1-IN-2 (Compound 4o) is an orally active AChE, BACE-1, and BChE inhibitor with IC50 values of 0.069, 0.097, and 0.127 μM against hAChE, hBACE-1, and hBChE, respectively. It exhibits remarkable antioxidant potential, considerable binding capability towards PAS-AChE, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress with excellent brain permeation [1].

BChE-IN-19 (Compound 7b), a para-substituted indone derivative, exhibits potent inhibitory activity against butyryl cholinesterase (BChE) with an IC50 value of 0.04 μM. It enhances cholinergic neurotransmission and has potential therapeutic application in Alzheimer's disease [1].

AChE BChE-IN-1 is a potent dual inhibitor of acetylcholinesterase and butyrylcholinesterase with blood-brain barrier permeability, exhibiting IC50 values of 1.06 nM for hAChE and 7.3 nM for hBChE, and showing antioxidant effects. AChE BChE-IN-1 can be used in Alzheimer's disease research.

BChE-IN-15 is a compound characterized as a pseudo-irreversible, covalent inhibitor of butyrylcholinesterase (BChE), demonstrating potent activity with an inhibitory concentration (IC50) of 1.76 nM against human BChE (hBChE).

AChE BChE-IN-21 is an antagonist of the histamine H3 receptor, a calcium channel blocker, and an acetylcholinesterase inhibitor. It exhibits neuroprotective activities against H2O2 and Aβ1-40, and can restore cognitive functions in AD mice.

AChE BChE-IN-20 (compound 3m) serves as an inhibitor for both acetylcholinesterase (AChE, IC50=34.81 µM) and butyrylcholinesterase (BChE, IC50=20.66 µM). The affinity for the critical enzyme pockets and the favorable interaction profiles were established through molecular docking and kinetics simulation, making it relevant for the study of Alzheimer's disease.